Modality
Nanobody
MOA
CGRPant
Target
GLP-1R
Pathway
Lipid Met
SCLCFSGS
Development Pipeline
Preclinical
Dec 2022
→ Sep 2029
PreclinicalCurrent
NCT03621309
1,232 pts·SCLC
2022-12→2026-07·Terminated
NCT07753810
1,072 pts·SCLC
2023-06→2029-09·Active
2,304 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-143mo awayInterim· SCLC
2029-09-023.4y awayInterim· SCLC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Termina…
Preclinical
Active
Catalysts
Interim
2026-07-14 · 3mo away
SCLC
Interim
2029-09-02 · 3.4y away
SCLC
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03621309 | Preclinical | SCLC | Terminated | 1232 | HAM-D |
| NCT07753810 | Preclinical | SCLC | Active | 1072 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Mavuglumide | Bayer | Approved | GLP-1R |